**Q Fever, Chronic (Coxiella burnetii)**

Merlin reporting code = 08302
Case report form (CRF): Q Fever CRF
PAPER CRF REQUIRED

**Clinical description**
Infection that persists for more than 6 months. Potentially fatal endocarditis may evolve months to years after acute infection, particularly in persons with underlying valvular disease. Infections of aneurysms and vascular prostheses have been reported. Immunocompromised individuals are particularly susceptible. Rare cases of chronic hepatitis without endocarditis, osteomyelitis, osteoarthritis, and pneumonitis have been described.

**Clinical criteria for case classification**
Newly recognized, culture-negative endocarditis, particularly in a patient with previous valvulopathy or compromised immune system, suspected infection of a vascular aneurysm or vascular prosthesis, or chronic hepatitis, osteomyelitis, osteoarthritis, or pneumonitis in the absence of other known etiology.

**Laboratory criteria for case classification**

**Confirmatory:**
- Serological evidence of IgG antibody to *Coxiella burnetii* phase I antigen $\geq 1:800$ by IFA (while phase II IgG titer will be elevated as well; phase I titer is higher than the phase II titer),
  OR
- Detection of *C. burnetii* DNA in a clinical specimen via amplification of a specific target by polymerase chain reaction (PCR),
  OR
- Demonstration of *C. burnetii* antigen in a clinical specimen by immunohistochemistry (IHC),
  OR
- Isolation of *C. burnetii* from a clinical specimen by culture.

**Presumptive:**
- Antibody titer to *C. burnetii* phase I IgG antigen $\geq 1:128$ and $< 1:800$ by IFA.

**Case classification**

**Confirmed:**
A clinically compatible chronic illness with confirmatory laboratory evidence for chronic infection.

**Probable:**
A clinically compatible chronic illness with presumptive laboratory evidence for past or present chronic infection (antibody to Phase I antigen).

**Comments**
Samples from suspected chronic patients should be evaluated for IgG titers to both phase I and phase II antigens. Current commercially available ELISA tests (which test only for phase 2) are not quantitative, cannot be used to evaluate changes in antibody titer, and hence are not useful for serological confirmation. IgM tests are not strongly supported for use in serodiagnosis of acute disease, as the response may not be specific for the agent (resulting in false positives) and the IgM response may be persistent. Complement fixation (CF) tests and other older test methods are neither readily available nor commonly used.
Serologic test results must be interpreted with caution, because baseline antibodies acquired as a result of historical exposure to Q fever may exist, especially in rural and farming areas.

Exposure is usually via aerosol, is broadly interpreted, and may be unknown (especially for chronic infection), but often includes the presence of goats, sheep, or other livestock, especially during periods of parturition. Direct contact with animals is not required, and variable incubation periods may be dose dependent.

Acute and convalescent sera from reported and suspect cases must be acquired and sent to the Bureau of Public Health Laboratories. This condition has been identified as a potential bioterrorism agent by the CDC.